Group 1 - The core viewpoint of the article indicates that the company's gross margin in the fourth quarter is expected to remain stable compared to the third quarter, primarily due to no significant changes in the product sales structure [2] - The company anticipates that high-value-added products expected to see increased sales volume in the fourth quarter include electrophysiology PFA products, peripheral balloons and microcatheters, peripheral dissolvable coils, second-generation coronary thin-walled sheaths, and hydrophilic-coated contrast tubes [2]

Core Viewpoint - The company expects its gross margin in Q4 to remain stable compared to Q3, with no significant changes in product sales structure [1] Group 1: Gross Margin Expectations - The company anticipates that the gross margin for Q4 will be similar to that of Q3, primarily due to a lack of significant changes in the sales structure of products [1] Group 2: Product Launches - Expected high-value products for Q4 include electrophysiology PFA products, peripheral balloons and microcatheters, peripheral dissolvable coils, second-generation coronary thin-walled sheaths, and hydrophilic-coated contrast tubes [1]